Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

USA - NASDAQ:ELUT - US05479K1060 - Common Stock

0.9094 USD
0 (-0.07%)
Last: 10/31/2025, 8:00:01 PM
Fundamental Rating

1

ELUT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. ELUT has a bad profitability rating. Also its financial health evaluation is rather negative. ELUT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELUT had negative earnings in the past year.
In the past year ELUT has reported a negative cash flow from operations.
ELUT had negative earnings in each of the past 5 years.
In the past 5 years ELUT always reported negative operating cash flow.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -63.63%, ELUT perfoms like the industry average, outperforming 41.01% of the companies in the same industry.
Industry RankSector Rank
ROA -63.63%
ROE N/A
ROIC N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K -3K -4K

1.3 Margins

With a decent Gross Margin value of 44.67%, ELUT is doing good in the industry, outperforming 74.91% of the companies in the same industry.
In the last couple of years the Gross Margin of ELUT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ELUT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ELUT has more shares outstanding
The number of shares outstanding for ELUT has been increased compared to 5 years ago.
ELUT has a worse debt/assets ratio than last year.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ELUT has an Altman-Z score of -11.81. This is a bad value and indicates that ELUT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.81, ELUT is doing worse than 75.84% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.81
ROIC/WACCN/A
WACC13.19%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 0.59 indicates that ELUT may have some problems paying its short term obligations.
The Current ratio of ELUT (0.59) is worse than 91.95% of its industry peers.
ELUT has a Quick Ratio of 0.59. This is a bad value and indicates that ELUT is not financially healthy enough and could expect problems in meeting its short term obligations.
ELUT has a worse Quick ratio (0.45) than 92.70% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.45
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.72% over the past year.
Looking at the last year, ELUT shows a very negative growth in Revenue. The Revenue has decreased by -25.25% in the last year.
The Revenue for ELUT have been decreasing by -10.69% on average. This is quite bad
EPS 1Y (TTM)67.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.65%
Revenue 1Y (TTM)-25.25%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-0.45%

3.2 Future

ELUT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.59% yearly.
The Revenue is expected to decrease by -9.47% on average over the next years.
EPS Next Y74.19%
EPS Next 2Y32.99%
EPS Next 3Y21.59%
EPS Next 5YN/A
Revenue Next Year-1.81%
Revenue Next 2Y2.19%
Revenue Next 3Y-9.47%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELUT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELUT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ELUT's earnings are expected to grow with 21.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.99%
EPS Next 3Y21.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELUT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELUTIA INC

NASDAQ:ELUT (10/31/2025, 8:00:01 PM)

0.9094

0 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-07 2025-11-07
Inst Owners39.78%
Inst Owner ChangeN/A
Ins Owners2.36%
Ins Owner Change4.05%
Market Cap38.56M
Revenue(TTM)23.68M
Net Income(TTM)-21537000
Analysts82.5
Price Target4.08 (348.65%)
Short Float %0.38%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.77%
Min EPS beat(2)-32.64%
Max EPS beat(2)52.18%
EPS beat(4)2
Avg EPS beat(4)11.01%
Min EPS beat(4)-32.64%
Max EPS beat(4)52.18%
EPS beat(8)2
Avg EPS beat(8)-38.99%
EPS beat(12)4
Avg EPS beat(12)-31.86%
EPS beat(16)5
Avg EPS beat(16)-27.71%
Revenue beat(2)0
Avg Revenue beat(2)-8.68%
Min Revenue beat(2)-11.1%
Max Revenue beat(2)-6.26%
Revenue beat(4)0
Avg Revenue beat(4)-9.63%
Min Revenue beat(4)-12.03%
Max Revenue beat(4)-6.26%
Revenue beat(8)2
Avg Revenue beat(8)-4.06%
Revenue beat(12)2
Avg Revenue beat(12)-5.1%
Revenue beat(16)4
Avg Revenue beat(16)-3.45%
PT rev (1m)-27.27%
PT rev (3m)-46.67%
EPS NQ rev (1m)-3.33%
EPS NQ rev (3m)11.43%
EPS NY rev (1m)-4.17%
EPS NY rev (3m)2.34%
Revenue NQ rev (1m)-10.14%
Revenue NQ rev (3m)-10.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.63
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0.56
BVpS-0.99
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.67%
FCFM N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
F-Score2
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.64%
Cap/Sales 4.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.45
Altman-Z -11.81
F-Score2
WACC13.19%
ROIC/WACCN/A
Cap/Depr(3y)14.22%
Cap/Depr(5y)13.83%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.65%
EPS Next Y74.19%
EPS Next 2Y32.99%
EPS Next 3Y21.59%
EPS Next 5YN/A
Revenue 1Y (TTM)-25.25%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-0.45%
Revenue Next Year-1.81%
Revenue Next 2Y2.19%
Revenue Next 3Y-9.47%
Revenue Next 5YN/A
EBIT growth 1Y21.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-79.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79%
OCF growth 3YN/A
OCF growth 5YN/A

ELUTIA INC / ELUT FAQ

Can you provide the ChartMill fundamental rating for ELUTIA INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELUT.


What is the valuation status for ELUT stock?

ChartMill assigns a valuation rating of 1 / 10 to ELUTIA INC (ELUT). This can be considered as Overvalued.


What is the profitability of ELUT stock?

ELUTIA INC (ELUT) has a profitability rating of 1 / 10.


What is the expected EPS growth for ELUTIA INC (ELUT) stock?

The Earnings per Share (EPS) of ELUTIA INC (ELUT) is expected to grow by 74.19% in the next year.